Literature DB >> 11160734

Human GLI-2 is a tat activation response element-independent Tat cofactor.

C M Browning1, M J Smith, N M Clark, B R Lane, C Parada, M Montano, V N KewalRamani, D R Littman, M Essex, R G Roeder, D M Markovitz.   

Abstract

Zinc finger-containing GLI proteins are involved in the development of Caenorhabditis elegans, Xenopus, Drosophila, zebrafish, mice, and humans. In this study, we show that an isoform of human GLI-2 strongly synergizes with the Tat transactivating proteins of human immunodeficiency virus types 1 and 2 (HIV-1 and -2) and markedly stimulates viral replication. GLI-2 also synergizes with the previously described Tat cofactor cyclin T1 to stimulate Tat function. Surprisingly, GLI-2/Tat synergy is not dependent on either a typical GLI DNA binding site or an intact Tat activation response element but does require an intact TATA box. Thus, GLI-2/Tat synergy results from a mechanism of action which is novel both for a GLI protein and for a Tat cofactor. These findings link the GLI family of transcriptional and developmental regulatory proteins to Tat function and HIV replication.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160734      PMCID: PMC114814          DOI: 10.1128/JVI.75.5.2314-2323.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

1.  Sending and receiving the hedgehog signal: control by the Drosophila Gli protein Cubitus interruptus.

Authors:  M Domínguez; M Brunner; E Hafen; K Basler
Journal:  Science       Date:  1996-06-14       Impact factor: 47.728

2.  Human homolog of patched, a candidate gene for the basal cell nevus syndrome.

Authors:  R L Johnson; A L Rothman; J Xie; L V Goodrich; J W Bare; J M Bonifas; A G Quinn; R M Myers; D R Cox; E H Epstein; M P Scott
Journal:  Science       Date:  1996-06-14       Impact factor: 47.728

Review 3.  Regulation of HIV-1 gene expression by the transactivator protein Tat.

Authors:  R B Gaynor
Journal:  Curr Top Microbiol Immunol       Date:  1995       Impact factor: 4.291

4.  Evidence for functional interaction between the HIV-1 Tat transactivator and the TATA box binding protein in vivo.

Authors:  P Veschambre; P Simard; P Jalinot
Journal:  J Mol Biol       Date:  1995-07-07       Impact factor: 5.469

5.  Viral transactivators specifically target distinct cellular protein kinases that phosphorylate the RNA polymerase II C-terminal domain.

Authors:  C H Herrmann; M O Gold; A P Rice
Journal:  Nucleic Acids Res       Date:  1996-02-01       Impact factor: 16.971

6.  Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor.

Authors:  C H Herrmann; A P Rice
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

Review 7.  Activation of HIV-1 transcription by Tat in cells derived from the CNS: evidence for the participation of NF-kappa B--a review.

Authors:  J P Taylor; K Khalili
Journal:  Adv Neuroimmunol       Date:  1994

8.  Control of transcription by Krüppel through interactions with TFIIB and TFIIE beta.

Authors:  F Sauer; J D Fondell; Y Ohkuma; R G Roeder; H Jäckle
Journal:  Nature       Date:  1995-05-11       Impact factor: 49.962

9.  A CNS-enriched factor that binds to NF-kappa B and is required for interaction with HIV-1 tat.

Authors:  J P Taylor; R J Pomerantz; J W Oakes; K Khalili; S Amini
Journal:  Oncogene       Date:  1995-01-19       Impact factor: 9.867

10.  Novel mechanism and factor for regulation by HIV-1 Tat.

Authors:  Q Zhou; P A Sharp
Journal:  EMBO J       Date:  1995-01-16       Impact factor: 11.598

View more
  2 in total

1.  GLI-2 modulates retroviral gene expression.

Authors:  M J Smith; S D Gitlin; C M Browning; B R Lane; N M Clark; N Shah; S Rainier; D M Markovitz
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  GLI2 regulates TGF-β1 in human CD4+ T cells: implications in cancer and HIV pathogenesis.

Authors:  Robert L Furler; Christel H Uittenbogaart
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.